|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/04/22 Mosaic ImmunoEngineering Inc. S-1 2/03/22 59:4.9M GlobalOne Filings Inc/FA |
Document/Exhibit Description Pages Size
1: S-1 Registration Statement (General Form) HTML 1.25M
2: EX-23.1 Consent of Kmj Corbin & Company LLP HTML 16K
3: EX-FILING FEES Calculation of Registration Fee HTML 28K
9: R1 Cover HTML 45K
10: R2 Consolidated Balance Sheets HTML 101K
11: R3 Consolidated Balance Sheets (Parenthetical) HTML 38K
12: R4 Consolidated Statements of Operations HTML 77K
13: R5 Consolidated Statements of Stockholders Equity HTML 88K
(Deficit)
14: R6 Consolidated Statements of Cash Flows HTML 102K
15: R7 Organization and Business HTML 35K
16: R8 Summary of Significant Accounting Policies HTML 61K
17: R9 Fair Value of Financial Instruments HTML 67K
18: R10 Investment in Affiliated Companies HTML 34K
19: R11 Accrued Expenses and Other Current Liabilities; HTML 26K
Accrued Payable to Founders
20: R12 License Agreements HTML 31K
21: R13 Convertible Notes HTML 28K
22: R14 Stockholders? Equity and Share-Based Compensation HTML 53K
23: R15 Income Taxes HTML 55K
24: R16 Commitments and Contingencies HTML 26K
25: R17 Related Parties HTML 26K
26: R18 Subsequent Events HTML 20K
27: R19 Summary of Significant Accounting Policies HTML 110K
(Policies)
28: R20 Summary of Significant Accounting Policies HTML 35K
(Tables)
29: R21 Fair Value of Financial Instruments (Tables) HTML 62K
30: R22 Investment in Affiliated Companies (Tables) HTML 22K
31: R23 Accrued Expenses and Other Current Liabilities; HTML 24K
Accrued Payable to Founders (Tables)
32: R24 Stockholders? Equity and Share-Based Compensation HTML 36K
(Tables)
33: R25 Income Taxes (Tables) HTML 49K
34: R26 Organization and Business (Details Narrative) HTML 48K
35: R27 Summary of Significant Accounting Policies HTML 36K
(Details - Reverse Merger)
36: R28 Summary of Significant Accounting Policies HTML 28K
(Details - anti-dilutive)
37: R29 Summary of Significant Accounting Policies HTML 22K
(Details Narrative)
38: R30 Fair Value of Financial Instruments (Details - HTML 41K
Fair Value)
39: R31 Fair Value of Financial Instruments (Details - HTML 28K
Assumption)
40: R32 Investment in Affiliated Companies (Details - HTML 48K
balance sheet)
41: R33 Investment in Affiliated Companies (Details HTML 29K
Narrative)
42: R34 Accrued Expenses and Other Liabilities (Details) HTML 26K
43: R35 Accrued Expenses and Other Current Liabilities; HTML 20K
Accrued Payable to Founders (Details Narrative)
44: R36 License Agreements (Details Narrative) HTML 40K
45: R37 Convertible Notes (Details Narrative) HTML 47K
46: R38 Stockholders' Equity and Share-Based Compensation HTML 21K
(Details - Share Based Compensation)
47: R39 Stockholders' Equity and Share-Based Compensation HTML 37K
(Details - RSU activity)
48: R40 Stockholders? Equity and Share-Based Compensation HTML 34K
(Details Narrative)
49: R41 Income Taxes (Details - Provision) HTML 41K
50: R42 Income Taxes (Details - Reconcilation) HTML 32K
51: R43 Income Taxes (Details - Deferred tax assets) HTML 38K
52: R44 Income Taxes (Details Narrative) HTML 38K
53: R45 Commitments and Contingencies (Details Narrative) HTML 21K
54: R46 Related Parties (Details Narrative) HTML 46K
57: XML IDEA XML File -- Filing Summary XML 106K
55: XML XBRL Instance -- mosaic_s1_htm XML 841K
56: EXCEL IDEA Workbook of Financial Reports XLSX 73K
5: EX-101.CAL XBRL Calculations -- cpmv-20211231_cal XML 134K
6: EX-101.DEF XBRL Definitions -- cpmv-20211231_def XML 377K
7: EX-101.LAB XBRL Labels -- cpmv-20211231_lab XML 716K
8: EX-101.PRE XBRL Presentations -- cpmv-20211231_pre XML 578K
4: EX-101.SCH XBRL Schema -- cpmv-20211231 XSD 113K
58: JSON XBRL Instance as JSON Data -- MetaLinks 291± 390K
59: ZIP XBRL Zipped Folder -- 0001683168-22-000669-xbrl Zip 275K
Exhibit 107
Calculation of Filing Fee Tables
S-1
(Form Type)
Mosaic ImmunoEngineering, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered Securities
| Security | Security | Fee | Amount | Proposed | Maximum | Fee Rate | Amount of | |||||||||||||||||||
| Type | Class | Calculation | Registered | Maximum | Aggregate | Registration | ||||||||||||||||||||
| Title | or Carry | Offering | Offering | Fee | ||||||||||||||||||||||
| Forward | Price Per | Price(1) | ||||||||||||||||||||||||
| Rule | Unit | |||||||||||||||||||||||||
| Fees to Be Paid | Equity | Units consisting of: (i) one share of Common Stock, par value $0.00001 per share (2) and (ii) one Warrant to purchase one share of Common Stock, par value $0.00001 per share (3) | 457(o) | $ | 17,250,000(1) | – | $ | 17,250,000 | 0.0000927 | $ | 1,599.08 | |||||||||||||||
| Fees to Be Paid | Equity | Shares of common stock, par value $0.00001 per share underlying warrants (2)(4) | 457(o) | $ | 20,700,000 | – | $ | 20,700,000 | 0.0000927 | $ | 1,918.89 | |||||||||||||||
| Fees to Be Paid | Equity | Underwriter Warrants to purchase shares of Common Stock (3)(4)(5) | 457(g) | – | – | – | – | – | ||||||||||||||||||
| Fees to Be Paid | Equity | Shares of Common Stock issuable upon exercise of Underwriter Warrants (2)(5) | 457(o) | $ | 1,035,000 | – | $ | 1,035,000 | 0.0000927 | $ | 95.94 | |||||||||||||||
| Total Offering Amounts | $ | 38,985,000 | $ | 3,613.91 | ||||||||||||||||||||||
| Total Fees Previously Paid | ||||||||||||||||||||||||||
| Total Fee Offset | ||||||||||||||||||||||||||
| Net Fee Due | $ | 3,613.91 | ||||||||||||||||||||||||
_______________
| (1) | Includes the offering price of Units that may be purchased by the underwriters pursuant to their option. | |
| (2) | Pursuant to Rule 416 under the Securities Act, there is also being registered hereby such indeterminate number of additional shares of common stock of the registrant as may be issued or issuable because of stock splits, stock dividends, stock distributions, and similar transactions. | |
| (3) | In accordance with Rule 457(i) under the Securities Act, no separate registration fee is required with respect to the warrants registered hereby. | |
| (4) | The warrants are exercisable at 120% of the public offering price (using maximum aggregate offering price of 120% of $17,250,000). | |
| (5) | The Registrant has agreed to issue, at the closing of this offering, warrants to the underwriters, entitling the underwriters to purchase 5% of the aggregate shares of common stock being sold in this offering. The exercise price of the warrants will be equal to 120% of the offering price of the common stock offered hereby. The estimated maximum aggregate offering price of the shares of common stock issuable upon exercise of the Underwriter Warrants was calculated to be $1,035,000, which is 120% of $862,500 (which is 5% of $17,250,000) | |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/10/21 Mosaic ImmunoEngineering Inc. 8-K:1,3,9 5/07/21 2:179K GlobalOne Filings Inc/FA 5/05/21 Mosaic ImmunoEngineering Inc. 10-Q 3/31/21 49:2.1M GlobalOne Filings Inc/FA 3/02/21 Mosaic ImmunoEngineering Inc. 10-KT 12/31/20 68:3.6M GlobalOne Filings Inc/FA 12/29/20 Mosaic ImmunoEngineering Inc. 10-Q 11/30/20 48:2.2M GlobalOne Filings Inc/FA 12/01/20 Mosaic ImmunoEngineering Inc. 8-K:3,5,8,911/30/20 5:652K GlobalOne Filings Inc/FA 11/02/20 Mosaic ImmunoEngineering Inc. DEF 14C 10/27/20 1:653K GlobalOne Filings Inc/FA 10/15/20 Mosaic ImmunoEngineering Inc. 10-Q 8/31/20 45:2M GlobalOne Filings Inc/FA 8/25/20 Mosaic ImmunoEngineering Inc. 8-K:1,2,3,5 8/19/20 7:1.1M GlobalOne Filings Inc/FA 8/11/08 Mosaic ImmunoEngineering Inc. 8-K:1,9 8/05/08 2:3.1M Publicease Inc./FA |